Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  veliparib
Find trials that include:  Any drugs shown
Results 1-24 of 24 for your search:
Start Over
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8329, NCI-2011-00312, 09-000742, CDR0000657976, MAYO-MC0861, MC0861, NCT01012817
Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8811, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, S1206, NCT01386385
Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-608, NCI-2013-00656, NCT01489865
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Gemcitabine Hydrochloride and Cisplatin with or without Veliparib or Veliparib Alone in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8993, NCI-2012-00864, CDR0000732189, IRB#12-045, MSKCC-12-045, 12-045, NCT01585805
Carboplatin and Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IIA-IIIC Breast Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12G.376, NCI-2013-00594, 2012001, 2012-47, 2997, NCT01818063
Cisplatin with or without Veliparib in Treating Patients with Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1416, NCI-2015-01912, NCT02595905
Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients with Stage III-IV Triple Negative Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10020, NCI-2016-01130, NCT02849496
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1513, NCI-2015-02248, NCT02890355
Veliparib and Irinotecan Hydrochloride in Treating Patients with Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: 7977, NCI-2009-01057, 2007-014, CDR0000579642, HIC1410014852, WSU-2007-014, NCT00576654
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
Veliparib and Dinaciclib in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-144, NCI-2011-03458, CDR0000710900, DFCI-11-144, 8484, NCT01434316
Veliparib and Radiation Therapy before Surgery in Treating Patients with Stage IIB-IV Breast Cancer with Incomplete Response to Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11155, NCI-2012-02760, CIR00006912, NA_00048362, NA_00048362 / CIR00004736, NCT01618357
Veliparib and Floxuridine in Treating Patients with Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1114, NCI-2012-02767, 9182, NCT01749397
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: M14-361, NCI-2015-00490, 2014-001764-35, NCT02289690
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, TBD, NCT02631733
Veliparib, ATR Kinase Inhibitor VX-970, and Cisplatin in Treating Patients with Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9771, NCI-2016-00355, P141582, 16-C-0087, NCT02723864
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9149, NCI-2013-01588, 130105, MPACT, P121047, 13-C-0105, NCT01827384
Veliparib and Lapatinib Ditosylate in Treating Patients with Triple Negative Metastatic Breast Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB1372, NCI-2015-00265, F131219003, NCI-2014-02253, NCT02158507
Start Over